Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
Clinical trial NCT02038647 · COMPLETED
Trial details
- NCT number
- NCT02038647
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-12
- Primary completion
- 2016-01-03
- Enrollment
- 178
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.